BioElectronics Corporation (OTC: BIEL) announced today the commercial launch of its ActiPatch device in Taiwan through its appointed distributor, Aphrodite Medical Group. This move introduces a drug-free, non-invasive pain therapy to the Taiwanese market, challenging conventional pharmaceutical approaches.
ActiPatch is a US FDA-cleared medical device that uses pulsed shortwave therapy to modulate pain at the peripheral nerve level. Each device provides up to 720 hours of continuous therapy and is designed for extended wear, including during sleep, offering a practical alternative to pain medications.
"The appointment of Aphrodite Medical Group establishes a strong commercial foundation for ActiPatch in Taiwan," said Kelly Whelan, CEO of BioElectronics Corporation. "Their clinical infrastructure and commitment to advanced patient care make them a capable partner to introduce and scale this therapy in a meaningful way."
Aphrodite Medical Group, a well-established healthcare provider in Taiwan with a broad clinical footprint, will lead market introduction, physician engagement, and patient access initiatives across its network and affiliated channels. The initial shipment of ActiPatch units has been completed, positioning the device for a coordinated market launch in Q2 2026. The rollout will initially focus on musculoskeletal pain management, with opportunities for expansion across additional clinical applications over time.
"We are pleased to bring ActiPatch to Taiwan as part of our commitment to delivering innovative, patient-centered therapies," said Yang Pei-Hsien, Vice President of Aphrodite Medical Group. "This technology aligns with the growing demand for safe, effective, and drug-free pain management options."
The Taiwan launch reinforces BioElectronics’ strategy to expand through high-quality distribution partnerships in key markets while maintaining focus on clinically validated, scalable bioelectronic therapies. This expansion comes amid growing concerns over opioid addiction and side effects from long-term painkiller use, highlighting the importance of non-pharmacological alternatives.
View the original release on NewMediaWire for more details.
